Previous Research

 
News Articles for Previous Research top ^
2015/2/6
http://www.marketwire.com/library/MwGo/2015/2/6/11G032571/Scotiabank-logo-780364326799.jpg TORONTO, ON--(Marketwired - February 06, 2015) - Scotiabank has released a revised Supplementary Financial Information Package pertaining to the presentation of financial information for fiscal 2014 and 2013, that reflects the integration of the Global Wealth & Insurance business line into Canadian Banking and International Banking as previously announced on September 5, 2014 (and effective November 1, 2014). In addition, Scotiabank also realigned its Asia operations that were previously reported in International Banking into Global Banking & Markets, with the exception of the associated corporations Thanachart Bank and Bank of Xi'an, which will continue to be reported in International Banking.
Sign-up for REPEAT: Scotiabank Releases Revised Supplementary Financial Information Package Reflecting Previously Announced Business Realignment investment picks
2015/2/25
TORC Announces Closing of the Previously Announced Strategic Acquisition in Southeast Saskatchewan Canada NewsWire CALGARY , Feb.
Sign-up for TORC Announces Closing of the Previously Announced Strategic Acquisition in Southeast Saskatchewan investment picks
2014/12/12
http://media3.marketwire.com/logos/20140213-200oly.jpg CALGARY, ALBERTA --
Sign-up for Olympia Confirms No Purchase Price Adjustment Required in Connection With Previous Sale of Corporate and Shareholder Services Assets investment picks
2015/1/9
Foundation Medicine, Inc. (NASDAQ:FMI) today announced that FoundationOne® , the company's flagship comprehensive genomic profile for patients with solid tumors, successfully identified clinically relevant genomic alterations in 65 percent of patients with lung adenocarcinoma whose tumors previously tested negative for alterations using multiple conventional approaches.
Sign-up for FoundationOne® Identifies High Frequency of Clinically Relevant Genomic Alterations (GA) Previously Missed by Conventional Genomic Tests, Enabling Successful Targeted Treatment in Patients with Non-Small Cell Lung Cancer investment picks
2015/1/30
Cominar Real Estate Investment Trust announces closing of previously-announced public offering of trust units Canada NewsWire /NOT FOR DISTRIBUTION IN THE UNITED STATES OR OVER UNITED STATES WIRE SERVICES/ QUÉBEC CITY, Jan.
Sign-up for Cominar Real Estate Investment Trust announces closing of previously-announced public offering of trust units investment picks
2015/2/3
Macy’s, Inc. (NYSE:M) today reported preliminary earnings per share for the full-year 2014 that are above previous guidance, as well as fourth quarter 2014 comparable sales consistent with expectations.
Sign-up for Macy’s, Inc. Expects Full-Year 2014 Earnings Per Share to Exceed Previous Guidance investment picks
2015/2/23
Celgene International Sàrl, a wholly owned subsidiary of Celgene Corporation (NASDAQ: CELG), today announced that the European Commission (EC) has approved REVLIMID ® (lenalidomide) for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for transplant.
Sign-up for ADDING MULTIMEDIA REVLIMID® (Lenalidomide) Approved by the European Commission for the Treatment of Adult Patients with Previously Untreated Multiple Myeloma who are Not Eligible for Transplant investment picks
2014/12/3
Pfizer Inc. (NYSE:PFE) announced today the publication of results from the PROFILE 1014 study in the December 4 issue of The New England Journal of Medicine .
Sign-up for Phase 3 Results Published in The New England Journal of Medicine Show Superiority of Pfizer’s XALKORI® (crizotinib) Compared to Platinum-Based Chemotherapy in Previously Untreated Patients With ALK-Positive Advanced Non-Small Cell Lung Cancer investment picks
2014/12/3
Hudson's Bay Company (“HBC” or the “Company”) (TSX: HBC) today announced that it has closed a US$1.25 billion, 20-year mortgage loan on the ground portion of its Saks Fifth Avenue flagship in New York City, located at 611 Fifth Avenue (the “Saks Ground Mortgage”). The Saks Ground Mortgage was made pursuant to a loan agreement dated December 3, 2014 with lenders Bank of America, N.A., Morgan Stanley Bank, N.A., Goldman Sachs Mortgage Company and The Bank of Nova Scotia.
Sign-up for Hudson’s Bay Company Closes Previously Announced US$1.25 Billion, 20-Year Mortgage Financing investment picks
2014/12/3
TAMPA, Fla., Dec.
Sign-up for Kforce Increases Previously Announced Quarterly Dividend 10% investment picks
2014/12/3
http://www.ccnmatthews.com/logos/20100511-GOBI%20LARGE.gif HONG KONG, CHINA --
Sign-up for SouthGobi Resources Announces the Successful Completion of the Previously Announced Private Placements and Payment of the Installment of Cash Interest Due on the CIC Convertible Debenture investment picks
2014/12/5
ALISO VIEJO, Calif.
Sign-up for Avanir Pharmaceuticals Cancels Previously Scheduled Earnings Call investment picks
2014/12/10
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1163974&ProfileId=051205&sourceType=1 ROSELAND, NJ --
Sign-up for ADP Regional Employment Report: All Four Major Regions Add Fewer Jobs in November Than Previous Six-Month Average investment picks
2014/12/8
95% (19/20) Overall Response Rate (ORR) in Patients with High-Risk CLL, the patient population to be studied in recently announced Phase 3 Clinical Trial being conducted under Special Protocol Assessment (SPA) 87% (34/39) ORR per iwCLL criteria in all evaluable CLL patients plus an additional 10% of patients with a nodal PR or nodal reductions ranging from 20%-45% without disease progression 88% (7/8) ORR in all evaluable Mantle Cell Lymphoma (MCL) patients with a 38% (3/8) Complete Response rate Combination of TG-1101 + Ibrutinib well tolerated with limited Grade 3/4 events reported to date SAN FRANCISCO, Dec.
Sign-up for Data From Phase 2 Clinical Trial of TG-1101 (Ublituximab) and Ibrutinib Shows Compelling Clinical Activity in Patients With Previously Treated, High-Risk Chronic Lymphocytic Leukemia (CLL) investment picks
2014/12/12
http://media3.marketwire.com/docs/logo_ANV_200.jpg RENO, NEVADA --
Sign-up for Allied Nevada Announces Closing of Previously Announced Public Offering of Common Stock and Warrants investment picks
2014/12/12
SPRINGFIELD, Mass.
Sign-up for Smith & Wesson Holding Corporation Completes Previously Announced Acquisition of Battenfeld Technologies, Inc. investment picks
2015/1/7
International Rectifier Corporation (NYSE:IRF) announced today that it expects closing of its pending merger with Infineon Technologies AG to occur on January 13, 2015.
Sign-up for International Rectifier Announces Expected Closing of Previously Announced Transaction investment picks

Premium Membership: Features and Benefits
Wide-Moat Screener for Stocks

Put a moat around your portfolio. Sniff out the most promising opportunities that can ride through any market.

Gold Medalist Screener for Funds

Narrow the available universe of 5000 funds to the top rated gold and silver. Then, sort for manager tenure, expense ratio, risk and return to create your own index-beating fund watchlist.

Thousands of Premium Analyst Reports

While many of our competitors measure a stock's worth with a computer program, Morningstar's staff of 150+ analyst sift through company fillings, financial data and a wealth of other sources to deliver an unvarnished review of any investment. In fact, twelve Morningstar analysts have been recognized by WSJ as "Best on the Street" in the US.

Premium Portfolio Monitor

Make decisions with confidence. Load your investments into our research center and automatically connect to all our proprietary tools and data points.

Mobile

Never be without critical research. Free with your active membership, take our Premium data and guidance wherever you go with Morningstar for iPad®, iPhone®, and Android apps.

Morningstar's Guarantee

We're looking out for you. If after your 14-day free trial, you find that a Morningstar Premium membership is not for you, cancel any time and we'll be happy to refund the unused portion - no questions asked.

Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Previous Research
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Title |  Date |  Author |  Collection |  Interest |  Popularity Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry |  Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry

Previous: Previous Announcement  |  Next: Price Advances